Literature DB >> 22902777

Importance of surveillance for multiple endocrine neoplasia-1 and surgery in patients with sporadic Zollinger-Ellison syndrome.

Maneesh H Singh1, Douglas L Fraker, David C Metz.   

Abstract

BACKGROUND & AIMS: Zollinger-Ellison syndrome (ZES) is a rare disorder characterized by gastrin-secreting tumors of the gastrointestinal tract and gastric acid hypersecretion. There is controversy over the best way to manage these patients; we investigated outcomes of patients with different forms of the disease, who did and did not undergo surgery.
METHODS: We performed a retrospective chart review of patients with ZES associated with multiple endocrine neoplasia type 1 (MEN-1) (n = 16) and those with sporadic ZES (n = 33) seen at a tertiary care center from August 1994 to January 2012. Cox proportional hazards modeling was used to compare survival times among groups, based on treatment with surgery (n = 34) and the presence of MEN-1 (n = 9 with surgery; n = 7 without surgery). Differences were compared using the unpaired Student t test and the Fisher exact test.
RESULTS: Patients with MEN-1 syndrome-associated ZES presented at a younger age than patients with sporadic ZES (34.9 vs 45.7 y, respectively; P < .05) and were diagnosed at a younger age (39.3 vs 49.7 y, respectively; P < .01), yet lived a similar number of years (55.9 vs 55.1 y, respectively; P = .91). None of the patients with MEN-1-associated ZES died of progressive disease, compared with 86% of deaths among patients with sporadic ZES (P < .05). Lymph node involvement, detected during surgery, increased the risk of metastasis to liver (P = .13) and lack of cure by surgery (P = .01). Surgery reduced all-cause mortality (hazard ratio, 0.11; 95% confidence interval, 0.2-0.6; P = .011) and disease-related mortality (hazard ratio, 0.14; 95% confidence interval, 0.2-0.84; P = .032) of patients with sporadic, but not MEN-1 syndrome-associated, ZES.
CONCLUSIONS: The presence of MEN-1 is associated with earlier onset and diagnosis of ZES, but a benign clinical course that rarely results in disease-related death; surgery therefore can be deferred for these patients. However, 86% of deaths among patients with sporadic ZES are attributed to disease-related causes, and mortality is reduced by early surgical intervention. Patients with sporadic ZES should undergo surgery soon after diagnosis.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22902777     DOI: 10.1016/j.cgh.2012.08.014

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  5 in total

1.  Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing.

Authors:  David C Metz; Guillaume Cadiot; Pierre Poitras; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Endocr Oncol       Date:  2017-10-11

2.  Weight Gain in Zollinger-Ellison Syndrome After Acid Suppression.

Authors:  Brian P Riff; David A Leiman; Bonita Bennett; Douglas L Fraker; David C Metz
Journal:  Pancreas       Date:  2016-02       Impact factor: 3.327

Review 3.  Multiple Endocrine Neoplasia: Genetics and Clinical Management.

Authors:  Jeffrey A Norton; Geoffrey Krampitz; Robert T Jensen
Journal:  Surg Oncol Clin N Am       Date:  2015-07-27       Impact factor: 3.495

4.  Prognostic factors and survival in MEN1 patients with gastrinomas: Results from the DutchMEN study group (DMSG).

Authors:  Dirk-Jan van Beek; Sjoerd Nell; Carolina R C Pieterman; Wouter W de Herder; Annenienke C van de Ven; Olaf M Dekkers; Anouk N van der Horst-Schrivers; Madeleine L Drent; Peter H Bisschop; Bas Havekes; Inne H M Borel Rinkes; Menno R Vriens; Gerlof D Valk
Journal:  J Surg Oncol       Date:  2019-08-10       Impact factor: 3.454

Review 5.  Multiple Endocrine Neoplasia Type 1: Latest Insights.

Authors:  Maria Luisa Brandi; Sunita K Agarwal; Nancy D Perrier; Kate E Lines; Gerlof D Valk; Rajesh V Thakker
Journal:  Endocr Rev       Date:  2021-03-15       Impact factor: 19.871

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.